States gain federal data on addiction medications under new reporting carve-out

What it does

This bill amends federal law to permit disclosure of substance use disorder medication records to state prescription drug monitoring programs (PDMPs) when state law requires it. Currently, federal privacy rules may restrict such disclosures; this bill creates a carve-out allowing states to receive data on opioid-addiction treatments and similar medications if their own laws mandate reporting.

Why we flagged it

The bill is a narrow technical amendment enabling state prescription drug monitoring programs to receive federal data on substance use disorder medications when state law requires it. It is a public-health coordination measure, not a deregulation or industry carve-out.

What the text implies

• Disclosure is conditional on state law requirement — states without such requirements receive no new data access, preserving federal privacy baseline for non-mandating states.
• The amendment does not mandate disclosure; it permits it where state law already requires it, meaning the bill removes a federal barrier to state-law compliance rather than creating new reporting obligations.
• Improved PDMP data on SUD medications may enable better detection of prescribing patterns, diversion, and coordination with addiction treatment, but effectiveness depends on state implementation and data quality.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens benefit from improved prescription monitoring and coordination between federal privacy protections and state drug-safety oversight. The bill does not weaken privacy — it aligns federal rules with state law requirements, enabling states to track controlled-substance prescribing patterns and detect diversion or overprescribing, which reduces overdose risk and supports addiction treatment coordination.

Named in the bill

Public Health Service Act, State prescription drug monitoring programs (PDMPs), Substance use disorder medications, 42 U.S.C. § 543(b)(2)

Where it stands

7 cosponsors: 6 Republicans, 1 Democrats.

• May 23, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 23, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $516,393 in lobbying spend. A filing names 13 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Mike Kennedy, the sponsor, reported $532,000 in PAC receipts in the 2026 cycle.

• American Society of Anesthesiologists — $496,393 on 2 filings
• American Organization for Nursing Leadership (formerly American Organization of — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.